Trial Profile
A Double-blind, Randomized, Parallel 2- Arm Study to Compare the Efficacy of Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes Who Are Receiving Background Standard-of-care Cardio-metabolic Therapy With Metformin, an Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker, and a Statin
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary) ; Hydrochlorothiazide
- Indications Hypertension in diabetes
- Focus Therapeutic Use
- 10 Jan 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Aug 2018 New trial record